2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Blood Banking, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Women’s Health, Adverse Events, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

2908 Novel LSD1 inhibitor bomedemstat induces fetal hemoglobin in sickle cell disease

Ying Guo, PhD, Uzor Ogbu, PhD, MBBS2, Jonas S. Samuel Jutzi, PhD3, Nicole Myer, PhD4, Patricia Marinello, PharmD5, Brian Long, PhD6, Doug Linn, PhD7
1 Merck & Co., Inc., Rahway, New Jersey, United States
2 Merck & Co., Inc., Rahway, New Jersey, United States
3 Merck & Co., Inc., Rahway, New Jersey, United States
4 Merck & Co., Inc., Rahway, New Jersey, United States
5 Merck & Co., Inc., Rahway, New Jersey, United States
6 Merck & Co., Inc., Rahway, New Jersey, United States
7 Merck & Co., Inc., Rahway, New Jersey, United States

Sickle cell disease (SCD) is a life-threatening genetic disorder that affects over 100,000 people in the United States and 8 million people worldwide, with an estimated 500,000 new births annually. SCD is caused by a single point mutation in the β-globin gene, producing abnormal hemoglobin S (HbS), which polymerizes under hypoxic conditions. This leads to red blood cell sickling, hemolytic anemia, vaso-occlusion, pain crises, and progressive organ damage. Clinical studies have demonstrated that induction of fetal hemoglobin (HbF) can ameliorate disease severity by inhibiting HbS polymerization, supporting HbF induction as a validated therapeutic strategy for SCD. Despite emerging advancements in therapies for SCD, hydroxyurea remains the mainstay of sickle cell therapy and the only approved oral HbF inducer. However, its variable patient response, long-term toxicities, and risks of malignancies limit its widespread adoption. Thus, development of alternative oral agents with disease modifying properties is the need of the hour. Epigenetic regulation of γ-globin expression represents a promising therapeutic approach for HbF induction. Lysine-specific demethylase 1 (LSD1) is a key epigenetic regulator that represses γ-globin expression. Inhibition of LSD1 has been shown to enhance γ-globin transcription and HbF production. In this study, we evaluated the effects of bomedemstat (MK-3543), a novel orally active irreversible LSD1 inhibitor, on HbF induction in human erythroid cells.

We utilized a three-phase culture system to differentiate erythroid cells from primary human CD34+ hematopoietic stem and progenitor cells (HSPCs) obtained from three healthy donors and three patients with SCD. Bomedemstat treatment was administered throughout an 11-day erythroid differentiation period, with hydroxyurea included as a comparator. HbF production was quantified by ion-exchange HPLC. In erythroid cells derived from healthy CD34+ donors, treatment with 10 nM bomedemstat significantly increased HbF level to 25.33 ± 3.06%, compared to 5.66 ± 4.04% in vehicle controls (p=0.0012, n=3) and 9.33 ± 3.51% in cells treated with 20 µM hydroxyurea (p=0.0036, n=3), representing 4.5-fold and 2.7-fold increases, respectively. Next, the proportion of HbF+ cells was assessed by flow cytometry. Bomedemstat (10 nM) significantly elevated the percentage of HbF+ cells compared to vehicle controls. Consistent with these findings, qRT-PCR analysis demonstrated that bomedemstat significantly upregulated γ-globin expression while downregulating β-globin, indicating a shift toward a fetal hemoglobin program. Importantly, similar effects were observed in erythroid cells derived from SCD patients, where 10 nM bomedemstat increased HbF levels to 23.33 ± 10.12%, compared to 6.33 ± 2.89% in controls, as measured by HPLC analysis (p=0.0489, n=3).

In summary, bomedemstat effectively induces HbF production in CD34+-derived erythroid cells from both healthy and SCD donors. These findings highlight bomedemstat as a promising therapeutic candidate for the treatment of sickle cell disease.

Ying Guo, PhD: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA - Stock (publicly traded); Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA - Current Employment